By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
Parkinson Plus Syndrome: For Those Searching for a Map on This Journey
For a family facing a new Parkinson Plus diagnosis, a map rests on five questions: how certain the diagnosis is, which supports suit which symptoms, which medicines need care, who belongs on the care team, and how to view unproven options. No treatment is known to stop these conditions. Options exist for symptoms, but the evidence for many is limited.
How certain is the diagnosis, and why does it matter?
The first question is which condition is meant and how sure the doctors are. The NHS says there is no single test for multiple system atrophy (MSA), progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD). Diagnosis rests on the symptoms and how they develop, and for PSP and CBD on the pattern of symptoms after other conditions have been ruled out. Krismer and colleagues add that MSA overlaps with Parkinson's disease and PSP, which makes a timely diagnosis hard.
The name matters because care and medicine cautions differ from one condition to another. You can ask the doctor: Which condition is suspected? How certain is the diagnosis? Which findings still leave other possibilities open? The names and how the conditions differ are explained on What is Parkinson Plus, early symptoms and daily life.
Which supports are named for each condition, and who provides them?
Supports are chosen by symptom, and care in every condition targets symptoms. The table gathers the options named in published guidance. Which of them suits a person is decided after an examination.
| Condition | Supports named | Limits |
|---|---|---|
| MSA | Medicines for dizziness and sleep problems, speech therapy for swallowing and communication, physiotherapy, occupational therapy (NHS) | No treatment stops it getting worse (NHS). No trial has yet clearly shown nerve protection in MSA (Krismer and colleagues) |
| PSP | Medicines for stiffness, physiotherapy, speech and language therapy, occupational therapy, botulinum toxin or special glasses for eye problems, a feeding tube for severe swallowing difficulty (NHS) | Levodopa often gives a small, short-lived benefit. Antidepressants are often poorly tolerated (Lamb and colleagues) |
| CBD | Medicines for stiffness, spasms, sleep, mood, pain or memory, therapies, palliative care (NHS). Baclofen or benzodiazepines for dystonia, levetiracetam or benzodiazepines for sudden muscle jerks (Lamb and colleagues) | Alzheimer medicines are used off-label (outside their approved use) with limited benefit (Lamb and colleagues) |
| Lewy body dementia (DLB) | Cholinesterase inhibitors (a group of dementia medicines) are called standard care for thinking and psychiatric symptoms. Memantine is an add-on in more severe dementia, with mixed results (Lewy Body Dementia Association) | Levodopa should start low and increase slowly, because people with DLB are prone to drug-induced psychosis (Lewy Body Dementia Association) |
Lamb and colleagues also name botulinum toxin for excess saliva, dystonia and eyelid spasm in PSP and CBD. Their review stresses that most recommendations come from other conditions, case series or expert opinion. For PSP and CBD they list the team as neurology, physiotherapy, occupational therapy, speech and language therapy, dietetics, ophthalmology, psychology and palliative care, and the NHS says CBD care includes palliative care. You do not have to build that team alone: ask the doctor which referrals are planned. The usual steps are on Parkinson Plus treatment, the care process.
Which medicines call for extra care?
In DLB, some medicines can cause serious harm. The Lewy Body Dementia Association says typical antipsychotics such as haloperidol should always be avoided. It says antipsychotics with a strong blocking effect on dopamine, such as olanzapine and risperidone, should also be avoided because of severe sensitivity to these drugs and a possibly fatal reaction called neuroleptic malignant syndrome. Quetiapine at a low dose is named as the preferred choice if one is needed. Dopamine agonists, amantadine and anticholinergics can worsen psychosis or thinking.
That guidance is dated 2015, so read it alongside current advice. For PSP and CBD, Lamb and colleagues say atypical antipsychotics are not recommended in older adults with dementia-related conditions, and most antipsychotics can worsen parkinsonism. The practical step is to tell any doctor or emergency department the diagnosis before a new medicine is started. If the person already takes one of these medicines, do not stop it on your own; ask the prescribing doctor promptly.
How should you approach questions about time?
Many families ask how much time there is, and the honest answer is that published figures are averages, not predictions. The NHS says the speed of progression in PSP varies widely. For CBD, it gives an average life expectancy of around 6 to 8 years from the start of symptoms, and stresses that this is an average with wide variation.
Reports count from different starting points, such as the first symptoms or diagnosis, so figures from different pages cannot be set side by side without care. Each figure and its limits are laid out on Parkinson Plus stages. Talking this through with the care team can make planning easier.
What can research and newer methods offer?
Research is active, but it has not yet produced a treatment that changes the course of these conditions. For MSA, Krismer and colleagues report that diagnostic criteria were revised in 2022 to improve accuracy in early disease, and that deposits of the protein alpha-synuclein have been better understood over the last five years. They write that early trial signals suggest a treatment that changes the disease may become possible, but no trial has yet clearly shown nerve protection. That is a reason for cautious interest, not a treatment today.
The evidence for brain stimulation methods such as transcranial magnetic stimulation (TMS) is also preliminary. The studies and their limits are described on Parkinson Plus and TMS.
When should you seek help without waiting?
If someone with DLB suddenly gets much worse after a new medicine, especially an antipsychotic, seek urgent help. The Lewy Body Dementia Association says people with DLB are prone to drug-induced psychosis and to reactions that can be fatal. Choking when swallowing, a cough with fever, breathlessness and fainting also should not wait, and choking that does not clear or severe breathlessness calls for emergency services. The NHS says swallowing problems in CBD can lead to pneumonia, which can be life-threatening, and lists dizziness or fainting among MSA symptoms.
Sources
- NHS: Multiple system atrophy (MSA)
- NHS: Progressive supranuclear palsy (PSP)
- NHS: Corticobasal degeneration
- Lamb and colleagues, Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options (2016)
- Lewy Body Dementia Association: Treatment Guidance and Medication Considerations in LBD (2015)
- Krismer and colleagues, Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment (2024)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Parkinson Plus